You are now leaving myCME and connecting to our educational partner. myCME does not control content, practices, or other policies of the site you are entering.
This CME-certified activity has been granted an extension for twelve months as the content was deemed relevant and current according to the standards set forth by the Society for Translational Oncology (STO) and Massachusetts General Hospital.
Release date: October 5, 2012
Review: October 18, 2013
Expiration date: October 18, 2014
1.00 / AMA PRA Category 1 Credit(s)TM
Estrogen- and/or progesterone-positive breast cancer is highly responsive to endocrine therapy. However, such cancers nearly always develop endocrine resistance. The most appropriate management options for women with endocrine-resistant breast cancer are unclear, so it’s critical for clinicians to remain informed about the most clinically relevant outcomes of trials presented/published in the past 18 months, in order to most effectively manage treatment-resistant MBC.
Community oncologists, surgical oncologists, radiation oncologists, pathologists, oncology nurses, and other health care professionals involved in the care and treatment of women with breast cancer.
At the end of this online enduring material, participants should be able to:
The following planner of this activity has indicated that she and/or her spouse/partner do have a relevant financial relationship to disclose:
Beverly Moy, MD
Consulting: GlaxoSmithKline, Pfizer
The Internet was selected as the medium for this activity to accommodate the learning preferences of a significant portion of the target audience.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The Society for Translational Oncology (STO) and Massachusetts General Hospital. The Society for Translational Oncology (STO) is accredited by the ACCME to provide continuing medical education (CME) for physicians.
Society for Translational Oncology designates this enduring material for a maximum of one (1) AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Method of Participation:
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.